S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
New CBOE “special perk” helps traders target income every weekend (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
New CBOE “special perk” helps traders target income every weekend (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
New CBOE “special perk” helps traders target income every weekend (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
New CBOE “special perk” helps traders target income every weekend (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

$5.12
-0.06 (-1.16%)
(As of 12/8/2023 ET)
Compare
Today's Range
$5.02
$5.19
50-Day Range
$4.70
$9.87
52-Week Range
$4.52
$16.90
Volume
1.42 million shs
Average Volume
2.62 million shs
Market Capitalization
$1.29 billion
P/E Ratio
28.44
Dividend Yield
N/A
Price Target
$13.90

Maravai LifeSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
171.5% Upside
$13.90 Price Target
Short Interest
Healthy
6.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.10) to ($0.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

353rd out of 933 stocks

Pharmaceutical Preparations Industry

138th out of 429 stocks


MRVI stock logo

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

MRVI Stock Price History

MRVI Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Maravai LifeSciences: Q3 Earnings Insights
Maravai LifeSciences Hosts 2023 Investor R&D Day
Maravai LifeSciences to Host 2023 Investor R&D Day
KeyBanc Downgrades Maravai LifeSciences
See More Headlines
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRVI
Fax
N/A
Employees
670
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.90
High Stock Price Target
$24.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+171.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$220.21 million
Pretax Margin
13.69%

Debt

Sales & Book Value

Annual Sales
$419.52 million
Cash Flow
$1.94 per share
Book Value
$3.55 per share

Miscellaneous

Free Float
250,730,000
Market Cap
$1.29 billion
Optionable
Not Optionable
Beta
-0.31
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Carl W. Hull (Age 64)
    Co-Founder & Executive Chairman
    Comp: $1.45M
  • Mr. William E. Martin III (Age 48)
    Chief Executive Officer
    Comp: $2.07M
  • Mr. Kevin M. Herde (Age 51)
    Executive VP & CFO
    Comp: $778.28k
  • Dr. Peter Michael Leddy Ph.D. (Age 60)
    Executive VP & Chief Administrative Officer
    Comp: $757k
  • Ms. Christine Dolan (Age 55)
    Executive Vice President of Biologics Safety Testing
    Comp: $755.97k
  • Ms. Debra Hart
    Senior Director of Investor Relations
  • Mr. Kurt Oreshack (Age 42)
    Executive VP, General Counsel & Secretary
    Comp: $701.4k
  • Ms. Becky Buzzeo
    Executive VP & Chief Commercial Officer
  • Dr. Kate E. Broderick Ph.D.
    Chief Innovation Officer
  • Mr. Christopher Benoit
    Executive Vice President of Enzymes














MRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRVI shares.
View MRVI analyst ratings
or view top-rated stocks.

What is Maravai LifeSciences' stock price target for 2024?

8 analysts have issued 1-year price objectives for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $24.00. On average, they anticipate the company's share price to reach $13.90 in the next twelve months. This suggests a possible upside of 171.5% from the stock's current price.
View analysts price targets for MRVI
or view top-rated stocks among Wall Street analysts.

How have MRVI shares performed in 2023?

Maravai LifeSciences' stock was trading at $14.31 at the start of the year. Since then, MRVI shares have decreased by 64.2% and is now trading at $5.12.
View the best growth stocks for 2023 here
.

When is Maravai LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our MRVI earnings forecast
.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The business earned $66.87 million during the quarter, compared to the consensus estimate of $75.23 million. Maravai LifeSciences had a net margin of 5.86% and a trailing twelve-month return on equity of 9.38%.

What ETFs hold Maravai LifeSciences' stock?
What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences updated its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of ($0.01) - $0.01 for the period, compared to the consensus EPS estimate of $0.06. The company issued revenue guidance of $275-285 million, compared to the consensus revenue estimate of $308.70 million.

When did Maravai LifeSciences IPO?

(MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (3.25%), 12 West Capital Management LP (2.57%), Mackenzie Financial Corp (1.96%), Braidwell LP (1.58%), Clearbridge Investments LLC (1.23%) and Jennison Associates LLC (1.01%).

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MRVI) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -